[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475752":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":38,"locations":47,"responsibleParty":64,"collaborators":67,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Shengjing Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Training cohort",null,"Training cohort was set to develop the novel non-invasive model for virtual HVPG",[13,14],"Device: 3D-MRE","Device: HVPG",{"label":16,"type":10,"description":17,"interventionNames":18},"Validation cohort","Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DEVICE","3D-MRE","All imaging studies were performed by using a 3.0-T MRI system ( GE Healthcare) with a phasedarray body coil.",[9,16],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"HVPG","HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.",[9,16],[30,33,36],{"name":31,"affiliation":5,"role":32},"Yu Shi, Prof.","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":35,"role":32},"Shenghong Ju, Prof.","Zhongda Hospital",{"name":37,"affiliation":35,"role":32},"Xiaolong Qi, Prof.",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Yifei Huang, M.D.","CONTACT","+86 158 0000 4518","huangyf1995@foxmail.com",{"name":31,"role":41,"phone":45,"phoneExt":10,"email":46},"+86 189 4025 9980","18940259980@163.com",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Shenyang","Liaoning","210000","China","CN",{"type":56,"coordinates":57},"Point",[58,59],123.43278,41.79222,{"lat":59,"lon":58},[62],{"name":63,"role":41,"phone":10,"phoneExt":10,"email":43},"Yifei Huang, MD",{"type":32,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yu Shi","Deputy director of department of radology",[68],{"name":35,"class":6},"100475752","3d-mre-for-assessing-cirrhosis-advanced-chronic-liver-disease-and-portal-hypertension-100475752",false,"NCT05475015","3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension","Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study","Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior.\n\nExclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.","ALL","18 Years","75 Years",{"count":80,"type":81},150,"ESTIMATED","OBSERVATIONAL","How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.",[85,86,87],"Cirrhosis, Liver","Portal Hypertension","Advanced Chronic Liver Disease",[22,26,89],"advanced chronic liver disease","2026-02-05",{"date":92,"type":93},"2026-02-09","ACTUAL",{"date":95,"type":93},"2022-08-16",{"date":97,"type":81},"2026-12-01",{"name":5,"class":6},1]